• HCMV-Driven AKT Inactivation via UL38-Mediated IRS1 Destabil

  2026-04-29

  This study reveals how human cytomegalovirus (HCMV) inactivates AKT by destabilizing insulin receptor substrate proteins through the viral protein UL38. The findings clarify a virus-host interaction central to HCMV replication and have direct implications for understanding signaling regulation in infected cells.

• Azithromycin as a Macrolide Antibiotic: Advanced Lab Workflo

  2026-04-28

  Leverage Azithromycin’s unique macrolide antibiotic mechanism for robust bacterial infection research, resistance profiling, and trypanosomosis models. This guide distills validated protocols, troubleshooting strategies, and actionable innovations—backed by APExBIO’s trusted quality—for reproducible, high-impact research.

• Applied Use Cases of Tris(2-carboxyethyl) Phosphine Hydrochl

  2026-04-28

  Tris(2-carboxyethyl) phosphine hydrochloride (TCEP hydrochloride) enables robust and odorless reduction of disulfide bonds, streamlining protein denaturation and assay sensitivity. Explore data-driven workflows, troubleshooting tactics, and the latest capture-and-release innovations for advanced diagnostics and proteomics.

• KR-12 Human Antimicrobial Peptide: Applied Workflows & Innov

  2026-04-27

  KR-12, the minimal human antimicrobial peptide, offers a focused approach to anti-biofilm, anti-inflammatory, and immunomodulatory research with exceptional specificity and low mammalian toxicity. This article translates recent breakthroughs into actionable protocols and troubleshooting strategies, guiding researchers to maximize KR-12’s translational impact in infection and inflammation models.

• BGJ398 (NVP-BGJ398): Optimizing FGFR-Driven Malignancy Resea

  2026-04-27

  BGJ398 (NVP-BGJ398) empowers oncology research with its nanomolar potency and selectivity for FGFR1/2/3, enabling precise modulation of signaling in FGFR-driven malignancies and developmental contexts. Discover how robust protocols, troubleshooting tips, and evidence-based workflows transform both cancer and developmental biology studies.

• IEM 1460: Applied Workflows for AMPA Receptor Blocker Resear

  2026-04-26

  IEM 1460 stands out as a highly selective AMPA receptor blocker, enabling precise investigations into excitotoxicity and neuroprotection. This guide delivers optimized protocols, troubleshooting strategies, and actionable insights for reliable AMPA receptor inhibition assays in neuroscience research.

• PD 0332991 (Palbociclib) HCl: Decoding CDK4/6 Inhibition and

  2026-04-25

  Explore the science behind PD 0332991 (Palbociclib) HCl, a leading CDK4/6 inhibitor, and discover novel insights into its antiproliferative mechanisms and RNA Pol II-mediated cell death. This article offers a unique, in-depth analysis for cancer research.

• Neuroligin 1 Proteolysis and Social Memory Maintenance in Mi

  2026-04-24

  Liu et al. (2025) reveal that social interaction-induced proteolysis of neuroligin 1 is critical for maintaining short-term social memory in mice by generating NLG1-CTD fragments that regulate synaptic plasticity. Their findings clarify how extracellular signaling events translate into persistent synaptic changes, offering new molecular insight into memory maintenance and its relevance to neuropsychiatric conditions.

• Alda 1: Advancing Cardioprotection and Regeneration via ALDH

  2026-04-24

  This thought-leadership article explores the mechanistic foundation, translational promise, and experimental guidance for leveraging Alda 1—a potent ALDH2 activator from APExBIO—in cardiac ischemia research and beyond. Integrating new mechanistic evidence, protocol optimization, and workflow strategies, it offers actionable insight for translational researchers aiming to harness aldehyde detoxification for cardioprotection and cardiac regeneration.

• IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in TNBC

  2026-04-23

  This study uncovers how the m6A reader IGF2BP3 stabilizes FZD1/7 transcripts to enhance stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC). The findings offer mechanistic insight into resistance pathways and identify the IGF2BP3–FZD1/7 axis as a therapeutic target to sensitize TNBC cells to platinum-based chemotherapy.

• Bleomycin Sulfate: Redefining Pulmonary Fibrosis Models

  2026-04-23

  Explore how Bleomycin Sulfate (Blenoxane) enables transformative insights into chemotherapy-induced DNA damage and pulmonary fibrosis. This thought-leadership piece blends mechanistic understanding—including IGF2BP1-driven macrophage metabolism and the TGF-β/Smad pathway—with strategic, evidence-backed guidance for translational researchers. By situating APExBIO’s Bleomycin Sulfate at the forefront of experimental innovation, we outline actionable protocols, benchmark its reliability, and map a forward-looking vision for next-generation fibrosis and oncology discovery.

• Maraviroc (UK-427857): Selective CCR5 Antagonist for HIV-1 E

  2026-04-22

  Maraviroc, also known as UK-427857, is a highly potent CCR5 antagonist that blocks HIV-1 entry and modulates neuroinflammatory signaling. Its nanomolar efficacy and specificity make it a critical tool for HIV tropism studies and neuroinflammation research.

• PKM2 Inhibitor (Compound 3k): Redesigning Cancer Metabolism

  2026-04-22

  Explore the mechanistic and strategic frontiers of PKM2 inhibitor (compound 3k), a selective pyruvate kinase M2 inhibitor from APExBIO. This thought-leadership article synthesizes the latest evidence on glycolytic modulation, tumor cell selectivity, and immunometabolic reprogramming, offering actionable insights and protocol guidance for translational researchers advancing cancer and inflammatory disease models.

• Dronedarone (Multaq): Mechanistic Horizons in AF Research

  2026-04-21

  This thought-leadership article examines the role of Dronedarone (Multaq) in atrial fibrillation (AF) and atrial flutter research, blending mechanistic insights with strategic guidance for translational scientists. Highlighting the latest findings on ion channel targeting, compound selectivity, and experimental best practices, it provides actionable recommendations for advancing cardiac arrhythmia pharmacology. This work distinguishes itself from routine product profiles by critically engaging with primary literature, interpreting cross-study evidence, and outlining future research imperatives.

• CD28-ARS2 Axis Regulates T Cell Metabolic Flexibility via PK

  2026-04-21

  This study uncovers how the CD28-ARS2 signaling axis drives alternative splicing of pyruvate kinase (PKM), promoting the PKM2 isoform over PKM1 in activated CD8+ T cells. This regulatory mechanism enhances metabolic flexibility and supports antitumor immunity, offering new insights for immunometabolic research.

466 records 21/32 page Previous Next First page 上5页 2122232425 下5页 Last page